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Strengths and limitations of this study
 ► To our knowledge, this study represents the first 
systematic review focused specifically on the effec-
tiveness of digital interventions for comorbid exces-
sive drinking and depression.
 ► This review has the potential to inform the develop-
ment of evidence-based interventions that could be 
delivered at scale to this at-risk population.
 ► The strengths of this systematic review include 
the use of an in-depth search strategy and robust 
quality appraisal criteria to identify and evaluate the 
existing literature.
 ► Potential limitations are likely to include be-
tween-study heterogeneity of the original studies 
and publication bias.
 ► Previous research in this field suggests that trials 
are likely to use a range of alcohol consumption and 
depression measures to assess outcomes.
AbStrACt
Introduction Excessive drinking and depression are 
frequently comorbid and make a substantial contribution 
to the global non-communicable disease burden. A 
range of effective interventions and treatments exist for 
either excessive drinking or depression alone, including 
a positive emerging evidence base for the use of digital 
interventions. Computerised and/or smartphone delivered 
advice could provide flexible, coordinated support for 
patients with comorbid excessive drinking and depression. 
However, to date, no systematic review of the evidence 
has been conducted focused on the effectiveness of 
digital interventions for this specific comorbid population. 
This systematic review will identify and evaluate the 
effectiveness of digital interventions for reducing comorbid 
excessive drinking and depression in community-dwelling 
populations.
Methods and analysis We will search MEDLINE, The 
Cochrane Library, CENTRAL, CINAHL, PsycINFO, ERIC and 
SCI from inception to end of July 2019 for randomised 
controlled trials that evaluate any personalised digital 
intervention for comorbid excessive drinking and 
depression and published in any language. Primary 
outcomes will be changes in quantity of alcohol consumed 
and depressive symptoms. Screening, data extraction and 
risk of bias assessment will be undertaken independently 
by two reviewers, with disagreements resolved through 
discussion. Meta-analytic methods will be used to 
synthesise the data collected relating to the primary 
outcomes of interest.
Ethics and dissemination As a systematic review, ethical 
approval is not needed. Findings will be published in peer-
reviewed journals and presented at conferences.
trial registration number CRD42019130134.
IntroduCtIon
description of the condition
Alcohol and mental health disorders make 
a substantial contribution to the global 
non-communicable disease burden.1 2 
Alcohol consumption alone is causally related 
to over 60 different medical conditions,3 with 
excessive drinking associated with adverse 
social and economic consequences that 
extend beyond the individual drinker to their 
families, communities and society as a whole.4 
Excessive drinking is defined here as either 
hazardous drinking, a pattern of alcohol 
consumption that increases an individual’s 
risk of harmful consequences,5 or harmful 
drinking, a pattern that is causing mental or 
physical damage.6 7 Excessive drinking is highly 
comorbid with a number of mental health 
conditions, including lifetime depression.8–10 
In the UK, over two-fifths of people presenting 
with excessive drinking in primary care suffer 
from depression,11 and an estimated one 
in five hospital admissions for mental and 
behavioural disorders are due to alcohol.12 
Experiencing such conditions comorbidly is 
associated with poorer overall outcomes for 
the individual concerned. Excessive drinking 
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is connected with: worsening the depression course, with 
risks of incident depression higher for heavier as opposed 
to lighter drinkers,13 increased suicide risk,14 and delayed 
recovery from psychiatric conditions.15
A range of effective interventions and treatments 
exist for either excessive drinking or depression alone, 
including behavioural (typically psychotherapy) deliv-
ered either face-to-face or computerised support, and/
or pharmacological approaches.16 17 In mild cases of 
depression, guided self-help and computerised cognitive 
behavioural therapy are recommended as initial treat-
ments18 19; while antidepressant drugs remain the main-
stay of treatment for moderate to severe or sustained cases, 
particularly selective serotonin reuptake inhibitors.20 For 
excessive drinking, there is strong evidence for the effec-
tiveness of brief behavioural advice for hazardous and 
harmful alcohol consumption delivered both face-to-face 
by primary care clinicians,16 and digitally, via website or 
smartphone application.21 Specialist treatment is recom-
mended for those drinking at dependent levels.22
For patients with comorbid excessive drinking and 
depression, the picture is more complex. Results for 
the use of cognitive-behavioural therapy and/or motiva-
tional interviewing for such individuals have been prom-
ising, demonstrating small but significant effects.23 24 
However, there is limited conclusive evidence concerning 
whether parallel or integrated treatment models achieve 
better treatment outcomes for such patients, particularly 
over the longer term.25 Thus, it is likely that multifac-
eted, sustained interventions will be needed, delivered 
concomitantly, and closely monitored, to optimise their 
overall impact.26–28 Given the positive emerging evidence 
base for the use of digital interventions with excessive 
drinking and depression alone,21 29–35 computerised 
and/or smartphone delivered advice and support could 
support the demand for flexible, more coordinated 
provision for patients experiencing such conditions 
comorbidly. Several trials suggest positive outcomes for 
digital interventions for comorbid excessive drinking and 
depression,36–40 but to date, no systematic review of the 
evidence has been conducted focused on this specific 
comorbid population. The proposed review aims to assess 
the effectiveness of digital interventions for reducing 
comorbid hazardous and harmful alcohol consumption 
and mild to moderate depression in community-dwelling 
populations.
MEthodS And AnAlySIS
This systematic review is registered with the International 
Prospective Register of Systematic Reviews (PROSPERO, 
https://www. crd. york. ac. uk/ PROSPERO). The protocol 
has been written according to the Preferred Reporting 
Items for Systematic Review and Meta-Analysis Protocols 
recommendations41 and the findings will be reported 
using Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) guidelines.42
Criteria for study inclusion
Population
Studies must be performed among community-dwelling 
adults (18 years and older), who have been identi-
fied by themselves, significant others or via a validated 
screening process as having comorbid excessive drinking 
and depression, and have personally sought out or been 
directed towards any digital intervention for comorbid 
excessive drinking and depression. Excessive drinking is 
defined here as either hazardous or harmful drinking.5–7 
Depression is defined as either major depression disorder, 
persistent depressive disorder or clinical depression 
assessed according to the WHO ICD-10 classification of 
mental and behavioural disorders ICD-107 or the Diag-
nostic and Statistical Manual of Mental Disorders (DSM-
5)6 by a standardised interview (eg, Structured Clinical 
Interview, Composite International Diagnostic Interview) 
or via validated self-reports or rating scales with specific 
cut-off points for depression. Studies will be excluded if 
interventions are directed mainly towards people who 
are seeking specialist health or social care for alcohol 
dependence and/or severe depression (such as inpa-
tient/residential programmes), or who were in treatment 
for, or recovery from, alcohol dependence (eg, 12‐step 
programmes).
Intervention
Must be digital, defined as being delivered primarily 
through a programmable computer or mobile device 
(laptop, phone, or tablet), including web-based, mobile 
phone text messaging, smart-phone applications, social 
networking, or ‘stand-alone’ computer-based technol-
ogies (CD-ROMs) and must respond to user input and 
generate personalised content which aims to address the 
participants’ alcohol-related behaviours and depression. 
Interventions which do not generate feedback or other 
output based on the personal characteristics of the user 
will not be included (eg, generic educational interven-
tions). Interventions are not restricted to those accessible 
online.
Comparator condition
No intervention, usual care (in a health or social care 
setting), or other digital or face to face brief intervention 
to reduce alcohol consumption and depression.
Outcomes
The primary outcomes will be1: quantity of alcohol 
consumed, which may be reported in standard drinks, 
alcohol units or similar, and which we will convert into 
grams of alcohol2; change in depressive symptoms, 
measured by a standardised or validated measure (Beck 
Depression Inventory (BDI)43; Hamilton Depression 
Rating Scale (HAM-D),44 Patient Health Question-
naire,45 Depression Anxiety Stress Scales,46 or any other 
depression scale). Where studies employ multiple vali-
dated rating scales for depression, preference would be 
for the BDI as a self‐rating scale and for the HAM‐D as 
copyright.
 o
n
 O
ctober 28, 2019 at Newcastle University. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-031503 on 17 October 2019. Downloaded from 
3Schulte B, et al. BMJ Open 2019;9:e031503. doi:10.1136/bmjopen-2019-031503
Open access
Table 1 MEDLINE search strategy
# Searches
1 exp Alcohol-Related Disorders/
2 exp Alcohol Drinking/
3 (alcohol$ adj2 (drink$ or intoxicat$ or use$ or abus$ or 
misus$ or risk$ or consum$ or withdraw$ or detox$ or 
treat$ or therap$ or excess$ or reduc$ or cessation or 
intervention$)).tw.
4 (drink$ adj2 (excess or heavy or heavily or harm or harmful 
or hazard$ or binge or harmful or problem$)).tw.
5 (“alcohol use” or alcoholic$).tw.
6 or/1–5
7 Depression/
8 exp Depressive Disorder/
9 Mood Disorders/
10 dysthymi$.tw.
11 (depressi$ adj3 disorder$).tw.
12 (depressi$ adj3 symptom$).tw.
13 mood disorder$.tw.
14 affective disorder$.tw.
15 antidepress$.tw.
16 anti-depress$.tw.
17 or/7–16
18 Internet/
19 Blogging/
20 Social Media/
21 Computers/
22 exp Microcomputers/
23 Minicomputers/
24 Therapy, Computer-Assisted/
25 Computer-Assisted Instruction/
26 exp Cellular Phone/
27 Electronic Mail/
28 ((email$ or e-mail$ or electronic mail$ or text messag$ or 
SMS or MMS or phone? or cellphone? or cell-phone? or 
smartphone? or smart-phone? or digital tablet? or pda 
or personal digital assistant? or social media or social 
networking or facebook or twitter or skyp$ or app?) adj3 
(deliver$ or generat$ or based or provid$ or facilitat$ or 
support$ or treatment? or therap$ or intervention? or 
program$ or feedback)).ti,ab.
29 ((Internet$ or electronic$ or digital$ or technolog$ or online 
or on-line or computer$ or laptop? or software or web$ 
or weblog$ or blog$ or CD? or CD-ROM?) adj3 (deliver$ 
or generat$ or based or provid$ or facilitat$ or support$ 
or treatment? or therap$ or intervention? or program$ or 
feedback)).ti,ab.
30 (e-BI or e-SBI or ehealth or e-health or electronic health or 
mhealth or m-health or mobile health or virtual health or 
digital health or technological aid?).ti,ab.
31 or/18–30
32 6 and 17 and 31
33 randomized controlled trial.pt.
34 controlled clinical trial.pt.
35 randomi*.ab.
Continued
an observer‐rating scale.47 In acknowledgment of the 
varied outcome measures currently employed in these 
fields,48 49 we will also include the following secondary 
outcomes of relevance: number of drinking days; number 
of heavy drinking days; number of drinks per drinking 
day; number of days abstinent; total abstinence; time to 
relapse; quality of life (measured by the 36‐item Short 
Form Health Survey50 or other validated tool); suicide‐
related behaviour (measured by deaths by suicide, suicide 
attempts, episodes of deliberate self-harm51); and any 
reported adverse effects. To be eligible for inclusion, 
studies must report outcomes for both alcohol consump-
tion and depression symptoms.
Setting
Participants may be recruited in a range of settings, 
including primary healthcare (including emergency 
departments), social care, educational, workplace or 
community. There is no restriction on where participants 
may interact with the intervention, given that it may be 
delivered through mobile devices.
Study type
Only randomised controlled trials (RCTs), with indi-
vidual, cluster, stepped wedge and n-of one designs, will 
be eligible for inclusion. We will exclude cross-sectional 
studies, case series and case reports.
Search strategy for identification of studies
We will search the following electronic databases from 
inception to identify studies for inclusion in the review: 
MEDLINE (Ovid); The Cochrane Library (Wiley); 
CENTRAL (Cochrane Central Register of Controlled 
Trials); CINAHL (EBSCO); PsycINFO (Ovid); ERIC 
(EBSCO); and SCI (Science Citation Index via Web of 
Knowledge). Additionally, potentially eligible studies 
included in the recent Cochrane Review of Personalised 
digital interventions for reducing hazardous and harmful 
alcohol consumption21 will be identified from electronic 
databases held by the authors. We will check reference 
lists of all included studies and other relevant reviews, 
carry out citation searches for included studies, and 
consult experts to confirm nothing has been missed. The 
search will not be limited by publication status, language 
or date. An example of the proposed search strategy for 
MEDLINE is outlined in table 1.
Study selection process
Following de-duplication of the search results, two 
researchers will independently screen all titles and 
abstracts identified, using Endnote to ensure consistency 
in screening approach. The full research papers of any 
studies identified as being potentially eligible will be 
reviewed by two researchers independently. Any discrep-
ancies will be resolved by discussion and by consulting 
a third researcher if necessary, to reach consensus. 
Reasons for exclusion from this phase of the search will 
be recorded. A PRISMA flow chart will outline the study 
selection process and reasons for exclusions.
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# Searches
36 placebo.ab.
37 drug therapy.fs.
38 randomly.ab.
39 trial.ab.
40 groups.ab.
41 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40
42 (animals not (humans and animals)).sh.
43 41 not 42
44 32 and 43
Table 1 Continued
data extraction
Data will be extracted using a standardised data extraction 
form specifically developed and piloted for this study. 
Extracted data will include: study design and setting; 
sample size including recruitment and retention rates; 
participant characteristics; details of the intervention 
(including mode of delivery); primary and secondary 
outcome measures (including SD or related measures 
of variability) and information for the assessment of the 
risk of bias. Two researchers will carry out data extraction 
of each included study independently, with any discrep-
ancies resolved by a third researcher. Where multiple 
eligible outcomes are recorded for depression, we will 
prioritise data from rating scales (eg, Hamilton Rating 
Scale for Depression) over self-report questionnaires (eg, 
BDI).
risk of bias
Two researchers will independently assess the risk of bias 
of the included studies using the Cochrane Collabora-
tion’s tool for assessing risk of bias in RCTs.52 For each 
included RCT, we will provide a description, comment 
and judgement of risk of bias for the following items1: bias 
arising from the randomisation process2; bias due to devi-
ations from intended interventions3; bias due to missing 
outcome data4; bias in measurement of the outcome5; 
bias in selection of the reported result (see online supple-
mentary appendix 1 for details). These judgments will 
be informed by the criteria adapted to the addiction 
field by the Cochrane Collaboration. Blinding of partic-
ipants, personnel and outcome assessor (avoidance of 
performance bias and detection bias) will be considered 
separately for objective outcomes (eg, drop out, use of 
substance of abuse measured by urine analysis, subjects 
relapsed at the end of follow-up, subjects engaged in 
further treatments) and subjective outcomes (eg, dura-
tion and severity of signs and symptoms of withdrawal, 
patient self-reported use of substance, side effects, social 
functioning as integration at school or at work, family 
relationship). Incomplete outcome data (avoidance of 
attrition bias) will be considered for all outcomes except 
for the drop out from the treatment, which is very often 
the primary outcome measure in trials on addiction.
Synthesis of data and summary measures
Data synthesis and meta-analysis
For all included RCTs, we will provide a detailed descrip-
tion of the results in both tables and text. If studies are 
sufficiently homogeneous to enable meta-analysis, we will 
pool the data for each outcome using a random-effects 
model in a meta-analysis that compares intervention and 
control arms, using mean differences or standardised 
mean differences as appropriate for continuous vari-
ables and relative risks for dichotomous outcomes. The 
meta-analysis will be performed using Review Manager 
(RevMan V5.3) developed by the Cochrane Community. 
If meta-analysis is not feasible, we will carry out a narrative 
summary of studies.
In the outcome assessment, for continuous variable 
outcomes (eg, quantity of alcohol consumed or scores 
in depression scales) we will compare standardised mean 
differences. For dichotomous outcomes (eg, participants 
classified as drinking over set limits or having depres-
sion remission), we will compare proportions using risk 
ratios. Where outcomes have been assessed at more than 
one time, data for each time point will be extracted. 
Depending on the availability of sufficient data, we will 
analyse follow-up durations using different time frames: 
(1) short term (up to 6 months postintervention); (2) 
medium term (6–12 months postintervention); and (3) 
long-term (more than 12 months postintervention).
Unit of analysis issues
For trials with more than one—and very similar—control 
or treatment arms, the results for these arms will be 
combined in the meta-analysis. If study arms cannot be 
combined, for example, due to important differences in 
intervention characteristics, each pair-wise comparison 
will be included separately. To avoid the multiple use of 
participants in the pooled estimate of treatment effect, 
every arm that is included more than once, will be divided 
by the number of comparisons where it is included.
For dichotomous outcomes, both the total number of 
patients and the number of events and will be divided up. 
For continuous outcomes, the means and SD will be left 
unchanged, and only the total number of participants will 
be divided. This method retains information from each 
arm of the trial while it compromises the precision of the 
pooled estimate slightly.
To allow the inclusion of cluster randomised trials with 
individually randomised trials in the same meta-anal-
ysis, we need to account for the relative variability within 
and between clusters. If a trial report only contains data 
that is not adjusted for the cluster design, we will add an 
external estimate of the intra-cluster coefficient to esti-
mate a design effect, thus inflating the variance of the 
effect estimate.
Dealing with missing data
We will contact authors to try to obtain missing data. 
Where this is impossible, we will attempt to estimate 
primary outcome measures using secondary outcome 
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measures; for example, estimating quantity of alcohol 
consumed using frequency and intensity of consumption. 
Trials with missing SD will be excluded from the main 
analysis for the associated continuous measure, but may 
be included in a sensitivity analysis, using imputed values 
for the SD.
Assessment of heterogeneity
Statistical heterogeneity will be assessed for significance 
with the Cochran’s Q test statistic, and quantified with the 
I2 value.53 Causes of heterogeneity will be explored both 
narratively and using subgroup and sensitivity analyses.
Assessment of publication bias
We will evaluate publication bias using the Egger test and 
funnel plots.54
Sensitivity analysis
We will conduct sensitivity analyses by investigating the 
effect of restricting to studies with a low overall risk of 
bias.
Patient and public involvement
Patients and the public were not involved in the design 
and will be not involved in the conduct of the review. 
However, we will discuss the findings with the Newcastle 
Mental Health Service User Patient and Public Involve-
ment Group and seek their assistance in interpreting the 
implications for policy and practice.
timeline
For the complete systematic review and meta-analysis, 
a timeline of 9 months is foreseen (1 April 2019–31 
December 2019).
Ethics and dissemination
As no primary data from studies will be collected, ethical 
approval is not needed for this systematic review. Findings 
will be published in peer-reviewed journals and presented 
at appropriate scientific conferences, congresses and 
symposia.
ConCluSIon
This review will examine the effectiveness of digital inter-
ventions for comorbid excessive drinking and depres-
sion. Digital interventions, delivered via computer or 
mobile phone, have the potential to provide cost-effec-
tive support for patients with excessive drinking and 
depression who may otherwise face socioeconomic and 
structural barriers to treatment. However, while previous 
studies have synthesised evidence of the impact of digital 
interventions on excessive drinking or depression alone, 
there is no comprehensive review that considers the effec-
tiveness of such interventions in comorbid populations. 
This review will respond to this knowledge gap, and thus 
has the potential to inform the development of evidence-
based interventions that could be delivered at scale to this 
at-risk population.
The strengths of this systematic review include the use 
of an in-depth search strategy and robust quality appraisal 
criteria to identify and evaluate the existing literature. 
However, potential limitations are likely to include 
between-study heterogeneity of the original studies and 
publication bias. Previous research in this field suggests 
that trials are likely to use a range of alcohol consumption 
and depression measures to assess outcomes.55 Further, 
while we will endeavour to retrieve data from eligible 
unpublished and non-significant studies, our findings 
could be limited by publication bias.56
In conclusion, to our knowledge, this study represents 
the first systematic review of digital interventions for 
comorbid excessive drinking and depression. Findings 
will have relevance for healthcare practitioners and poli-
cy-makers, as well as helping to inform the direction of 
future research in this field.
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